SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation (CDXC) on August 14, 2019, reporting events occurring on August 13, 2019. The filing details the entry into a Material Definitive Agreement regarding a private placement financing. Note: The request metadata referenced "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics
- Financing Amount: $7.0 million aggregate gross proceeds.
- Security Type: Common Stock, par value $0.001 per share.
- Purchase Price: $4.465 per share.
- Placement Agent Fees: 5.0% of proceeds generated by Oppenheimer & Co. Inc.; 2.5% of other proceeds; plus expense reimbursement.
- Advisory Fees: Non-creditable quarterly fee of $50,000 (July 1, 2019 to July 1, 2020).
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide specific values for these operational metrics.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement to raise capital. The transaction is expected to close on August 15, 2019, subject to customary closing conditions. The shares are being sold pursuant to exemptions under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D to accredited investors.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the completion, timing, and size of the financing. Management notes that actual results may differ materially due to risks associated with satisfying closing conditions. The company refers investors to the "Risk Factors" section of its Annual Report on Form 10-K for the year ended December 31, 2018, for a comprehensive list of risks. The company explicitly states it has no obligation to update forward-looking statements.
Investor Verification Checklist
- Confirm the closing of the $7.0 million financing on or after August 15, 2019.
- Verify the exact number of shares issued based on the $4.465 per share price.
- Review the full text of the Securities Purchase Agreement (Exhibit 99.1) for specific covenants and conditions.
- Assess the impact of the 5.0% and 2.5% placement fees and the $50,000 quarterly advisory fees on net proceeds.
- Check subsequent filings for any updates on the use of proceeds or changes in the company's liquidity position.